ArticlePharmacology research & perspectives2020

A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment.

Karthick Vishwanathan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.